long intergenic non-protein coding RNA 1224Genealiases: []
Q-omics provides the consensus-scored LINC01224 profile across patient tissues and cancer cell-line models. LINC01224 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC01224 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LINC01224 RNA expression shows 14,684 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LIHC, KIRC, and TGCT as cancer lineages where LINC01224 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01224 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01224 survival associations across molecular data types. LINC01224 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01224 RNA expression–survival associations across cancer types. High LINC01224 expression shows unfavorable associations in LIHC, UCEC and LGG, but favorable associations in UVM, BRCA and UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC01224 RNA expression.
This table summarizes LINC01224 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01224. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01224 shows lower tumor expression in KIRC and higher tumor expression in STAD, THCA, BRCA, LIHC and LUSC. The KIRC box plot shows higher LINC01224 RNA expression in normal versus tumor tissue (log2 FC = −0.786, t-test p < 0.001).
This table shows molecular features associated with LINC01224 in patient tissues and cancer cell lines. In patient samples, LINC01224 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
